BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 7, 2011
View Archived Issues
BD Diagnostics files for FDA clearance for fully automated molecular assays for herpes
Read More
New antagonists of melanin-concentrating hormone MCH1 receptor claimed
Read More
New inhibitors of FADK 1, JAK2 and JAK3 described
Read More
X-ray crystallography provides insight into formation of complement convertase
Read More
Triheptanoin has anticonvulsant effects in models of epilepsy
Read More
PanOptica raises funds to develop topical treatment for AMD
Read More
Insulin PharmFilm is tested in primates
Read More
Mercator Therapeutics and Pepscan Therapeutics join to optimize anticancer homing peptides
Read More
Almirall and Forest Labs report on aclidinium bromide trials
Read More
AnaptysBio triggers milestone payment from Merck & Co.
Read More
Bioniche Life Sciences raises funds to support several programs
Read More
Anadys begins phase IIb study of ANA-598 in hepatitis C
Read More
FDA lifts clinical hold on phase II Alferon LDO trial in influenza
Read More
Cellzome researchers describe novel ZAP-70 inhibitors
Read More
Invega approved in E.U. for schizoaffective disorder
Read More
Novel B-raf inhibitors discovered at Nerviano Medical Sciences
Read More
New ligands of transient receptor potential TRPM8 channel patented
Read More
Santarus and Depomed resume Glumetza distribution in U.S.
Read More
SuperGen enrolls first patient in phase I SGI-110 trial in MDS and AML
Read More
Omeros licenses new antifibrinolytic agents from University of California
Read More
Algeta completes enrollment into phase III Alpharadin trial
Read More
Avila Therapeutics designs irreversible and selective HCV protease inhibitors
Read More
Enrollment complete in EXPAND trial of Erbitux in gastric cancer
Read More
Cynapsus and IntelGenx sign definitive license agreement for INT-0010
Read More
Gold-bound TNF-alpha formulation CYT-6091 enters clinic
Read More